A report about an 80-year-old patient with advanced Alzheimer's disease who showed remarkable improvement after taking psilocybin mushrooms, also known as "magic mushrooms," has sparked the interest of researchers.
Although this fungus is known for its ability to induce hallucinations, the case has led researchers to question whether its active compound could be used to affect the aging brain.
The patient had been experiencing a gradual decline for a decade, communicating only in single words, becoming dependent on others, and suffering from difficulty walking and urinary incontinence. After ingesting 5 grams of the mushroom, she sweated profusely and fell into a deep sleep. Nineteen hours later, she suddenly began speaking and recalling memories.
In the following days, her condition improved significantly. She became more alert, recognized her family, and regained the ability to walk, dress, and control her bladder. However, the researchers emphasize that this report does not prove that psilocybin reverses Alzheimer's disease. It is an isolated case, not a controlled clinical trial. The diagnosis was not confirmed by biomarkers, and there was no control group or standardized memory tests. Furthermore, Alzheimer's disease involves profound biological changes such as the accumulation of abnormal proteins, inflammation, and the death of nerve cells, and there is no evidence that psilocybin reverses these processes.
Researchers hypothesize that psilocybin may have temporarily altered the way brain networks communicate, making some hidden abilities available for a limited time. This explanation relies on the brain's well-known capacity for adaptation and reorganization, a process called neuroplasticity.
Animal studies have shown that psilocybin can promote the growth of new connections between nerve cells and may also have anti-inflammatory effects, which is important because inflammation contributes to Alzheimer's. However, these hypotheses remain unproven, especially since the report did not include brain imaging.
This report comes amid growing scientific interest in psilocybin, which has shown promising results in treating depression and anxiety, but whether these effects apply to Alzheimer's patients remains unknown.
Experts strongly caution against interpreting this case as evidence of the effectiveness or safety of magic mushrooms. Psilocybin, the active ingredient, is not risk-free, especially for the elderly, and can cause serious side effects. They emphasize that answering open questions about the role of psilocybin and the replication of these results requires controlled research, and that its use outside of a supervised research setting is extremely dangerous and scientifically unjustified.
